Major Depressive Disorder News and Research RSS Feed - Major Depressive Disorder News and Research

Self-serving bias impaired in individuals suffering from MDD

Self-serving bias impaired in individuals suffering from MDD

Neuropsychological impairment has long been established as a fundamental characteristic of depression, but a specific pattern of impairment that is widely recognized has not been summarized. [More]
NIH funds Phase II 90-subject pediatric clinical trial at UCLA

NIH funds Phase II 90-subject pediatric clinical trial at UCLA

NeuroSigma, Inc., a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that the U.S. National Institutes of Health (NIH) has awarded UCLA a grant that funds a Phase II 90-subject pediatric clinical trial at the University of California, Los Angeles focused on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with NeuroSigma's external trigeminal nerve stimulation (eTNS) System. [More]
Patients in new DSM-5 bipolar category ‘deserve attention’

Patients in new DSM-5 bipolar category ‘deserve attention’

People who fall into the DSM-5 Other Specified Bipolar and Related Disorders category carry a significant clinical burden, a study shows. [More]
Breckenridge announces launch of Duloxetine Delayed-release Capsules

Breckenridge announces launch of Duloxetine Delayed-release Capsules

Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Duloxetine Delayed-release Capsules. [More]
New guidelines aim to improve delivery of prostate cancer survivorship care

New guidelines aim to improve delivery of prostate cancer survivorship care

New American Cancer Society Prostate Cancer Survivorship Care guidelines released today outline posttreatment clinical follow-up care for the myriad of long-term and late effects an estimated 2.8 million prostate cancer survivors in the United States may face. [More]
Alkermes initiates FORWARD-3 and FORWARD-4 efficacy studies in pivotal clinical program for ALKS 5461

Alkermes initiates FORWARD-3 and FORWARD-4 efficacy studies in pivotal clinical program for ALKS 5461

Alkermes plc today announced the initiation of FORWARD-3 and FORWARD-4, two of the three planned phase 3 core efficacy studies in the pivotal clinical program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD). [More]
Predictive factors ‘raise suspicion’ for emergence of bipolar disorder

Predictive factors ‘raise suspicion’ for emergence of bipolar disorder

Researchers have identified seven factors that predict which patients initially diagnosed with depression will later meet the diagnostic criteria for bipolar disorder. [More]
Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Two studies of the anti-depressive drug duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), compared its effectiveness and safety to either fluoxetine or placebo in children and adolescents with major depressive disorder (MDD). [More]
Biomarker predicts bipolarity in depressed patients

Biomarker predicts bipolarity in depressed patients

Measuring plasma levels of brain-derived neurotrophic factor in patients with a first episode of depression could help to predict who will go on to develop bipolar disorder, research suggests. [More]
Naurex's two lead antidepressant programs achieve major milestones

Naurex's two lead antidepressant programs achieve major milestones

Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones. [More]
Pernix completes sale of Pernix Manufacturing to Woodfield Pharmaceutical

Pernix completes sale of Pernix Manufacturing to Woodfield Pharmaceutical

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced that it has closed on the sale of its Houston, TX-based manufacturing operations, Pernix Manufacturing, LLC ("PML") to Woodfield Pharmaceutical LLC. [More]
Intranasal ketamine spray confers rapid antidepressant effect in patients with depressive disorder

Intranasal ketamine spray confers rapid antidepressant effect in patients with depressive disorder

A research team from the Icahn School of Medicine at Mount Sinai published the first controlled evidence showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect -within 24 hours-and was well tolerated in patients with treatment-resistant major depressive disorder. [More]
Deutsche Forschungsgemeinschaft to establish 5 new Research Units

Deutsche Forschungsgemeinschaft to establish 5 new Research Units

Topics Range from Composite Structures to Personnel Decisions to Metastatic Cancer Progression / About Eleven Million Euros in Funding for Three Years [More]
NeuroSigma gets approval to market Monarch eTNS System in Australia

NeuroSigma gets approval to market Monarch eTNS System in Australia

NeuroSigma, Inc., a California-based life-sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that it has received approval from the Therapeutic Goods Administration to market its Monarch eTNS System in Australia. [More]
Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities. [More]
Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine in patients with bipolar depression. [More]
Seroxat in combination with acupuncture produces significant effect in patients with unipolar depression

Seroxat in combination with acupuncture produces significant effect in patients with unipolar depression

Acupuncture is more effective than oral antidepressants in improving depressive symptoms, and produces fewer side effects than tricyclic antidepressants. [More]
New report provides link between poor health and multiple forms of discrimination

New report provides link between poor health and multiple forms of discrimination

Racial and sexual minorities, women, and obese people may face more health risks because of their disproportionate exposure to discrimination, according to a new report in the Journal of Health and Social Behavior. [More]
Adolescence is key developmental period for obesity and depression

Adolescence is key developmental period for obesity and depression

Depression and obesity have long been associated, but how they relate over time is less clear. New research from a Rutgers University-Camden professor shows that adolescent females who experience one of the disorders are at a greater risk for the other as they get older. [More]
Illness course impacts suicide risk in bipolar and depressive disorder

Illness course impacts suicide risk in bipolar and depressive disorder

Differing illness course, rather than the illness itself, is the greatest determinant of the differential risk of suicide attempts between patients with bipolar disorder and those with major depressive disorder, study findings indicate. [More]